Source: Clinical rheumatology. Unidade: FM
Subjects: VACINAS VIRAIS, COVID-19, DOENÇAS AUTOIMUNES, ESTUDOS PROSPECTIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PASOTO, Sandra Gofinet et al. Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity. Clinical rheumatology, v. 41, n. 7, p. 2079-2089, 2022Tradução . . Disponível em: https://doi.org/10.1007/s10067-022-06134-x. Acesso em: 22 maio 2024.APA
Pasoto, S. G., Halpern, A. S. R., Guedes, L. K. N., Ribeiro, A. C. M., Yuki, E. N. F., Silva, C. A. A. da, et al. (2022). Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity. Clinical rheumatology, 41( 7), 2079-2089. doi:10.1007/s10067-022-06134-xNLM
Pasoto SG, Halpern ASR, Guedes LKN, Ribeiro ACM, Yuki ENF, Silva CAA da, Kupa L de VK, Leon EP, Bispo FRS, Bonfa ESD de O. Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity [Internet]. Clinical rheumatology. 2022 ; 41( 7): 2079-2089.[citado 2024 maio 22 ] Available from: https://doi.org/10.1007/s10067-022-06134-xVancouver
Pasoto SG, Halpern ASR, Guedes LKN, Ribeiro ACM, Yuki ENF, Silva CAA da, Kupa L de VK, Leon EP, Bispo FRS, Bonfa ESD de O. Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity [Internet]. Clinical rheumatology. 2022 ; 41( 7): 2079-2089.[citado 2024 maio 22 ] Available from: https://doi.org/10.1007/s10067-022-06134-x